Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis
Authors' conclusion
High ADA_ab levels are a significant predictor of LOR in JIA patients treated with adalimumab, particularly when coupled with low drug levels.
Study context
- Population
- Juvenile Idiopatihc Arthritis (JIA) patients treated with adalimumab, December 2016 to May 2024
- Participants
- 184 patients
- Exposure
- Higher vs lower anti-adalimumab antibody and adalimumab drug levels
- Outcome
- Loss of response (LOR), defined as active disease
Methodological detailslongitudinal, random-forest and multiple logistic regression, Kaplan-Meier analysis
- Longitudinal
- Random-forest and multiple logistic regression
- Kaplan-Meier analysis
Main finding
As reported in the abstract
LOR
Odds ratio (95% CI)P value
Higher ADA_ab levelsmultiple logistic regression; independent association
1.18(1.08–1.29)
P = 0.0003Higher ADA_drug levelsmultiple logistic regression
0.81(0.68–0.95)
P = 0.0103ADA_ab threshold of 69 AU/mLeightfold increase in LOR
8.04(2.8–26.1)
P = 0.0002High ADA_ab and undetectable ADA_drughighest risk of LOR
28.24(7.11–111.63)
P = 0.0001Observational data: associations, not effects.
Further findings
Loss of response (LOR) within 12 months in patients with elevated ADA_ab (Kaplan-Meier)
- Patients with elevated ADA_ab experiencing LOR
- 71%
Original publication
Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. Published 25 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →